AGN-199201 Vehicle

DRUG5 trials

Sponsors

Allergan

Conditions

ErythemaPresbyopiaRosacea

Phase 1

Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea

CompletedNCT01579084

AllerganErythema, Rosacea

Start: 2012-04-30End: 2012-06-30Updated: 2019-11-18

Phase 2

AGN-199201 for the Treatment of Erythema With Rosacea

CompletedNCT01735201

AllerganErythema, Rosacea

Start: 2012-12-31End: 2013-06-30Updated: 2019-11-18

Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia

CompletedNCT02197806

AllerganPresbyopia

Start: 2014-07-31End: 2014-11-30Updated: 2015-12-03

A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia

CompletedNCT02595528

AllerganPresbyopia

Start: 2016-04-29End: 2017-10-18Updated: 2020-12-22

A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia

CompletedNCT02780115

AllerganPresbyopia

Start: 2016-05-26End: 2017-10-31Updated: 2020-12-22

Related Papers

Safety and Efficacy of AGN-190584 in Individuals With Presbyopia

JAMA Ophthalmology2022-03-0345 citations

Development of the Near Vision Presbyopia Task-based Questionnaire for use in evaluating the impact of presbyopia.

2021-12-023 citations

Development of the Presbyopia Impact and Coping Questionnaire.

2021-10-137 citations